Tags

Type your tag names separated by a space and hit enter

High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).
J Thromb Haemost 2010; 8(1):114-20JT

Abstract

BACKGROUND

In cancer patients, laboratory parameters that predict venous thromboembolism (VTE) are scarce. Increased platelet count has been found to be a risk factor for VTE in cancer patients receiving chemotherapy (CHT). We have assessed high platelet count as a risk predictor for VTE in patients with cancer undergoing discriminative anti-cancer treatments and investigated whether platelet count correlates with thrombopoietin (TPO) levels.

DESIGN AND METHODS

The Cancer and Thrombosis Study (CATS) is an ongoing prospective observational study of patients with newly diagnosed cancer or progression of disease, which started in October 2003. Occurrence of VTE and information on the patients' anti-cancer treatment during follow-up were recorded.

RESULTS

Between October 2003 and February 2008, 665 patients with solid tumors were included (314 female/351 male, mean age 62 years). VTE occurred in 44 patients (18 female/26 male, mean age 62 years). The cumulative probability of VTE after 1 year was 34.3% in patients with a platelet count (PC) above the 95th percentile representing 443 x 10(9)/L compared with 5.9% in those below 443 x 10(9)/L. High platelet count [hazard ratio (HR): 3.50, 95% confidence interval (CI): 1.52-8.06, P = 0.0032], soluble P-selectin [HR: 2.66, 95% CI: 1.42-4.96, P = 0.0021] and surgery [HR: 4.05, 95% CI: 1.74-9.46, P = 0.0012] were statistically significant risk factors for VTE in multivariable analysis along with leucocyte count, age, gender, radio- and CHT. We found no correlation between platelet count and TPO levels.

CONCLUSIONS

High PC is a clinically important, independent risk predictor for VTE in cancer patients. PC was not found to be associated with TPO levels.

Authors+Show Affiliations

Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19889150

Citation

Simanek, R, et al. "High Platelet Count Associated With Venous Thromboembolism in Cancer Patients: Results From the Vienna Cancer and Thrombosis Study (CATS)." Journal of Thrombosis and Haemostasis : JTH, vol. 8, no. 1, 2010, pp. 114-20.
Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost. 2010;8(1):114-20.
Simanek, R., Vormittag, R., Ay, C., Alguel, G., Dunkler, D., Schwarzinger, I., ... Pabinger, I. (2010). High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Journal of Thrombosis and Haemostasis : JTH, 8(1), pp. 114-20. doi:10.1111/j.1538-7836.2009.03680.x.
Simanek R, et al. High Platelet Count Associated With Venous Thromboembolism in Cancer Patients: Results From the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost. 2010;8(1):114-20. PubMed PMID: 19889150.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). AU - Simanek,R, AU - Vormittag,R, AU - Ay,C, AU - Alguel,G, AU - Dunkler,D, AU - Schwarzinger,I, AU - Steger,G, AU - Jaeger,U, AU - Zielinski,C, AU - Pabinger,I, Y1 - 2009/11/02/ PY - 2009/11/6/entrez PY - 2009/11/6/pubmed PY - 2010/5/21/medline SP - 114 EP - 20 JF - Journal of thrombosis and haemostasis : JTH JO - J. Thromb. Haemost. VL - 8 IS - 1 N2 - BACKGROUND: In cancer patients, laboratory parameters that predict venous thromboembolism (VTE) are scarce. Increased platelet count has been found to be a risk factor for VTE in cancer patients receiving chemotherapy (CHT). We have assessed high platelet count as a risk predictor for VTE in patients with cancer undergoing discriminative anti-cancer treatments and investigated whether platelet count correlates with thrombopoietin (TPO) levels. DESIGN AND METHODS: The Cancer and Thrombosis Study (CATS) is an ongoing prospective observational study of patients with newly diagnosed cancer or progression of disease, which started in October 2003. Occurrence of VTE and information on the patients' anti-cancer treatment during follow-up were recorded. RESULTS: Between October 2003 and February 2008, 665 patients with solid tumors were included (314 female/351 male, mean age 62 years). VTE occurred in 44 patients (18 female/26 male, mean age 62 years). The cumulative probability of VTE after 1 year was 34.3% in patients with a platelet count (PC) above the 95th percentile representing 443 x 10(9)/L compared with 5.9% in those below 443 x 10(9)/L. High platelet count [hazard ratio (HR): 3.50, 95% confidence interval (CI): 1.52-8.06, P = 0.0032], soluble P-selectin [HR: 2.66, 95% CI: 1.42-4.96, P = 0.0021] and surgery [HR: 4.05, 95% CI: 1.74-9.46, P = 0.0012] were statistically significant risk factors for VTE in multivariable analysis along with leucocyte count, age, gender, radio- and CHT. We found no correlation between platelet count and TPO levels. CONCLUSIONS: High PC is a clinically important, independent risk predictor for VTE in cancer patients. PC was not found to be associated with TPO levels. SN - 1538-7836 UR - https://www.unboundmedicine.com/medline/citation/19889150/High_platelet_count_associated_with_venous_thromboembolism_in_cancer_patients:_results_from_the_Vienna_Cancer_and_Thrombosis_Study__CATS__ L2 - https://doi.org/10.1111/j.1538-7836.2009.03680.x DB - PRIME DP - Unbound Medicine ER -